DNA vs IDNA

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on DNA as a result. In 72 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.

The Moving Average Convergence Divergence (MACD) for DNA just turned positive on November 10, 2026. Looking at past instances where DNA's MACD turned positive, the stock continued to rise in 40 of 51 cases over the following month. The odds of a continued upward trend are 78%.

The 50-day moving average for DNA moved above the 200-day moving average on October 07, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +24.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNA advanced for three days, in 209 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The 10-day RSI Indicator for DNA moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 20 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for DNA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. DNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.809) is normal, around the industry mean (3.498). P/E Ratio (-2.258) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.397) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on IDNA as a result. In 76 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.

Following a +5.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDNA advanced for three days, in 243 of 283 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 58 cases where IDNA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.

The Moving Average Convergence Divergence Histogram (MACD) for IDNA turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 46 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

IDNA broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.